Consolidated Financial Results
for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS)

July 31, 2026

Company name	: **ONO PHARMACEUTICAL CO., LTD.**
Stock exchange listing	: Tokyo Stock Exchange
Securities Code	: 4528
URL	: https://www.ono-pharma.com/en
Representative	: Toichi Takino President
Inquiries	: Ryuta Imura Vice president of Corporate Communications
Telephone	: +81-(0)6-6263-5670
Scheduled date of dividend payment commencement	: －
Supplementary materials for the quarterly financial results	: Yes
Earnings announcement for the quarterly financial results	: Yes (for institutional investors and securities analysts)

(Note: Amounts of less than one million yen are rounded.)

1. Consolidated Financial Results for the First Quarter of FY2026 (April 1, 2026 to June 30, 2026)

(1) Consolidated Operating Results (cumulative)

IFRS (Full) basis (% change from the same period of the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the period		Profit attributable to owners of the Company		Total comprehensive income for the period	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY2026 Q1	116,160	(8.9)	30,653	39.4	31,250	38.0	24,163	37.0	24,151	36.7	34,888	413.3
FY2025 Q1	127,536	8.4	21,995	(28.3)	22,650	(32.0)	17,631	(29.0)	17,673	(28.7)	6,797	(81.4)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
FY2026 Q1	51.40	51.38
FY2025 Q1	37.62	37.58

Core basis

	Revenue		Core operating profit		Core profit for the period		Basic core earnings per share
	Million yen	%	Million yen	%	Million yen	%	Yen
FY2026 Q1	116,160	(8.9)	38,681	22.5	30,221	21.9	64.31
FY2025 Q1	127,536	8.4	31,566	(10.1)	24,799	(13.7)	52.79

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets
	Million yen	Million yen	Million yen	%
As of June 30, 2026	1,084,413	872,740	866,831	79.9
As of March 31, 2026	1,106,515	856,643	850,727	76.9

2. Dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of First quarter	End of fiscal year	Total
	Yen	Yen	Yen	Yen	Yen
FY2025	－	40.00	－	40.00	80.00
FY2026	－				
FY2026 (Forecast)		40.00	－	40.00	80.00

(Note) Revisions to dividend forecast most recently announced: None

Consolidated Financial Forecast for FY2026 (April 1, 2026 to March 31, 2027)

IFRS (Full) basis (% change from the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the year		Profit attributable to owners of the Company		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
FY2026	455,000	(11.8)	94,000	1.9	94,000	1.5	71,000	1.6	71,000	1.8	151.09

Core basis (% change from the previous fiscal year)

	Revenue		Core operating profit		Core profit for the year		Basic core earnings per share
	Million yen	%	Million yen	%	Million yen	%	Yen
FY2026	455,000	(11.8)	124,000	(9.6)	93,000	(10.1)	197.91

(Note) Revisions to financial forecast most recently announced: None

Notes

(1) Significant changes in scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates
1) Changes in accounting policies required by IFRS: None
2) Changes in accounting policies due to other than (2) – 1) above: None
3) Changes in accounting estimates: None

(3) Number of shares issued and outstanding (common stock)
1) Number of shares issued and outstanding as of the end of the period (including treasury shares):
As of June 30, 2026 498,692,800 shares
As of March 31, 2026 498,692,800 shares
2) Number of treasury shares as of the end of the period:
As of June 30, 2026 28,785,627 shares
As of March 31, 2026 28,785,489 shares
3) Average number of shares outstanding during the period:
Three months ended June 30, 2026 469,904,825 shares
Three months ended June 30, 2025 469,771,044 shares

Note: The Company has introduced an ESOP Trust for stock grants. Shares of the Company held by the Trust are included in treasury shares, which are deducted when calculating the number of treasury shares at the end of the period and the weighted average number of shares outstanding during the period.

* Review of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Note to ensure appropriate use of forecasts, and other comments in particular
Forecasts and other forward-looking statements included in this report are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Please refer to "(4) Future Outlook" on page 5 for information regarding the consolidated financial forecasts.

Index of the Attachment

1. Overview of Operating Results and Other Information

(1) Overview of Operating Results for the 1st Quarter of Fiscal Year 2026

① Overview of Financial Results (Core basis)

(Millions of yen)

	Three months ended June 30, 2025	**Three months ended June 30, 2026**	Change	Change (%)
Revenue	127,536	**116,160**	(11,376)	(8.9)%
Core operating profit	31,566	**38,681**	7,116	22.5%
Core profit for the period (attributable to owners of the Company)	24,799	**30,221**	5,422	21.9%

[Revenue]

Revenue totaled ¥116.2 billion, which was a decrease of ¥11.4 billion (8.9%) from the corresponding period of the previous fiscal year (year on year).

<Sales of Domestic Goods and Products>

- Sales of domestic products decreased by ¥26.0 billion (35.0%) year on year to ¥48.1 billion.
  The decline was primarily attributable to the termination of the co-promotion agreement with AstraZeneca for Forxiga Tablets, resulting in no sales being recorded for the product in the current period (¥25.1 billion in the same period of the previous fiscal year). In addition, sales of Opdivo Intravenous Infusion for malignant tumors decreased by ¥1.2 billion (4.1%) year on year to ¥28.2 billion, mainly due to the intensified competitive environment.
  Sales of Ongentys Tablets for the treatment of Parkinson’s disease increased by ¥0.4 billion (16.9%) year on year to ¥2.6 billion, driven by continued market penetration. Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis, increased by ¥0.2 billion (10.0%) year on year to ¥2.4 billion, mainly due to broader adoption of CKD-MBD (chronic kidney disease-mineral and bone disorder) management in line with treatment guidelines. Sales of Braftovi Capsules for malignant tumors increased by ¥0.7 billion (51.1%) year on year to ¥2.0 billion, mainly due to expanded use in first-line treatment for colorectal cancer.

<Sales of Overseas Goods and Products>

- Sales of overseas products increased by ¥6.1 billion (44.8%) year on year to ¥19.8 billion.
  Sales of QINLOCK® (ripretinib) for gastrointestinal stromal tumor, marketed by Deciphera Pharmaceuticals, LLC, the operating company of Deciphera Pharmaceuticals, Inc., increased by ¥2.8 billion (31.5%) year on year to ¥11.7 billion driven by broader adoption and appropriate use in the GIST treatment area. Sales of ROMVIMZA® (vimseltinib), also marketed by Deciphera, for tenosynovial giant cell tumor (TGCT) treatment increased by ¥3.1 billion (289.3%) year on year to ¥4.1 billion, reflecting expansion into additional markets, including in Europe.

<Royalty and Others>

- Royalty and others increased by ¥8.5 billion (21.2%) year on year to ¥48.2 billion, mainly due to an increase in royalty revenue from Bristol-Myers Squibb Company.

[Core Operating Profit]

Core operating profit was ¥38.7 billion, an increase of ¥7.1 billion (22.5%) year on year.

- Cost of sales decreased by ¥7.5 billion (26.5%) year on year to ¥20.6 billion mainly due to the termination of the co-promotion agreement for Forxiga Tablets.
- Research and development costs decreased by ¥3.8 billion (10.6%) year on year to ¥32.4 billion mainly due to the absence of expenses recorded in the same period of the previous fiscal year in connection with the drug discovery collaboration agreement with LigaChem Biosciences, as well as one-time clinical development costs to Bristol-Myers Squibb, despite increases in research costs.
- Selling, general, and administrative expenses (except for research and development costs) decreased by ¥7.2 billion (23.1%) year on year to ¥23.9 billion mainly due to the termination of the co-promotion agreement for Forxiga Tablets and the promotion of cost efficiency.

[Core profit for the period] (attributable to owners of the Company)

Core profit attributable to owners of the Company increased by ¥5.4 billion (21.9%) year on year to ¥30.2 billion in association with the increase of the profit before tax.

② Overview of Financial Results (IFRS (Full) basis)

The consolidated financial results (full-year basis) for the period were as shown in the table below.
Operating profit, profit before tax, and profit attributable to owners of the Company all increased compared with the same period of the previous fiscal year.

(Millions of yen)

	Three months ended June 30, 2025	**Three months ended June 30, 2026**	Change	Change (%)
Revenue	127,536	**116,160**	(11,376)	(8.9)%
Operating profit	21,995	**30,653**	8,658	39.4%
Profit before tax	22,650	**31,250**	8,600	38.0%
Profit for the period (attributable to owners of the Company)	17,673	**24,151**	6,478	36.7%

The full-base results include items that are excluded from the core-basis results, such as amortization of intangible assets and the expense associated with the step-up in inventory to fair value.
In the current period, amortization of intangible assets amounted to ¥6.0 billion (¥6.2 billion in the same period of the previous fiscal year), and the expense associated with the step-up in inventory to fair value amounted to ¥2.0 billion (¥2.7 billion in the same period of the previous fiscal year).

A reconciliation from IFRS (full-basis) results to core-basis results is presented below.

(Billions of Yen)

	IFRS (Full) basis	**Core Adjustment**		**Core basis**
		Amortization	**Others**	
Sales revenue	**116.2**			**116.2**
Cost of sales	**(28.7)**	6.0	2.0	**(20.6)**
Gross profit	**87.5**	6.0	2.0	**95.5**
SG&A expenses	**(23.9)**			**(23.9)**
R&D costs	**(32.4)**			**(32.4)**
Other income	**0.1**			**0.1**
Other expenses	**(0.6)**			**(0.6)**
Operating profit	**30.7**	6.0	2.0	**38.7**
Operating profit ratio	**26.4%**			**33.3%**
Finance income	**1.4**			**1.4**
Finance costs	**(0.8)**			**(0.8)**
Profit before tax	**31.3**	6.0	2.0	**39.3**
Income tax	**(7.1)**	(1.5)	(0.5)	**(9.0)**
Profit for the period	**24.2**	4.5	1.5	**30.2**
Non-controlling	**0.0**			**0.0**
Profit for the period (Attributable to owners of the company)	**24.2**	4.5	1.5	**30.2**

(2) Overview of Financial Position for the 1st Quarter of Fiscal Year 2026

(Millions of yen)

	As of March 31, 2026	**As of June 30, 2026**	Change
Total assets	1,106,515	**1,084,413**	(22,102)
Equity attributable to owners of the Company	850,727	**866,831**	16,104
Ratio of equity attributable to owners of the Company to total assets	76.9%	**79.9%**	
Equity attributable to owners of the Company per share	1,810.44 yen	**1,844.69 yen**	

Total assets decreased to ¥1,084.4 billion by ¥22.1 billion from the end of the previous fiscal year.
Current assets decreased by ¥31.8 billion to ¥436.6 billion mainly due to decreases in “cash and cash equivalents” and “trade and other receivables”.
Non-current assets increased by ¥9.7 billion to ¥647.9 billion mainly due to increases in investment securities.
Liabilities decreased by ¥38.2 billion to ¥211.7 billion mainly due to decreases in income tax payables and “trade and other payables”.
Equity attributable to owners of the Company increased by ¥16.1 billion to ¥866.8 billion mainly due to the recording of the profit for the period and an increase in other components of equity, despite cash dividends.

(3) Overview of Cash Flows for the 1st Quarter of Fiscal Year 2026

(Millions of yen)

	Three months ended June 30, 2025	**Three months ended June 30, 2026**	Change
Cash and cash equivalents at the beginning of the period	204,567	**237,046**	
Cash flows from operating activities	3,373	**1,053**	(2,320)
Cash flows from investing activities	(43,043)	**3,423**	46,465
Cash flows from financing activities	(25,757)	**(21,850)**	3,906
Net increase (decrease) in cash and cash equivalents	(65,426)	**(17,374)**	
Effects of exchange rate changes on cash and cash equivalents	(150)	**(130)**	
Cash and cash equivalents at the end of the period	138,991	**219,542**	

Net increase/decrease in cash and cash equivalents was a decrease of ¥17.4 billion.
Net cash provided by operating activities was ¥1.1 billion, as a result of profit before tax of ¥31.3 billion, etc., despite income tax paid of ¥30.2 billion.
Net cash provided in investing activities was ¥3.4 billion, as a result of proceeds from sales of intangible assets of ¥8.4 billion, etc., despite purchases of intangible assets of ¥3.6 billion and purchases of property, plant, and equipment of ¥2.0 billion etc.
Net cash used in financing activities was ¥21.9 billion, as a result of dividends paid of ¥17.5 billion, and repayments of long-term loans of ¥7.5 billion, etc.

(4) Future Outlook

There are no changes from the consolidated financial forecast for the year ending March 31, 2027, announced on May 8, 2026.

2. Basic Approach to the Selection of Accounting Standards

Our group has applied International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2014, for the purpose of improving comparability by disclosing financial information based on international standards and enhancing the convenience of various stakeholders such as shareholders, investors, and business partners.

3. Condensed Interim Consolidated Financial Statements and Major Notes

(1) Condensed Interim Consolidated Statement of Financial Position

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	237,046	219,542
Trade and other receivables	145,936	130,994
Marketable securities	60	80
Other financial assets	1,565	1,575
Inventories	57,451	55,754
Other current assets	26,249	28,606
Total current assets	468,308	436,551
Non-current assets		
Property, plant, and equipment	101,419	100,898
Goodwill	22,654	23,009
Intangible assets	353,581	354,955
Investment securities	93,193	102,558
Other financial assets	8,109	8,064
Deferred tax assets	55,759	55,001
Other non-current assets	3,492	3,375
Total non-current assets	638,206	647,862
Total assets	1,106,515	1,084,413

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities and Equity		
Current liabilities		
Trade and other payables	62,951	49,376
Short-term loans	35,389	39,420
Lease liabilities	3,078	2,890
Other financial liabilities	1,472	4,121
Income taxes payable	30,778	9,044
Other current liabilities	29,976	28,110
Total current liabilities	163,645	132,961
Non-current liabilities		
Long-term loans	75,000	67,500
Lease liabilities	7,468	7,290
Other financial liabilities	0	0
Retirement benefit liabilities	2,234	2,505
Deferred tax liabilities	909	847
Other non-current liabilities	616	570
Total non-current liabilities	86,227	78,712
Total liabilities	249,871	211,673
Equity		
Share capital	17,358	17,358
Capital reserves	17,378	17,389
Treasury shares	(62,770)	(62,770)
Other components of equity	48,674	59,497
Retained earnings	830,086	835,356
Equity attributable to owners of the Company	850,727	866,831
Non-controlling interests	5,917	5,909
Total equity	856,643	872,740
Total liabilities and equity	1,106,515	1,084,413

(2) Condensed Interim Consolidated Statement of Income and Condensed Interim Consolidated Statement of Comprehensive Income

Condensed Interim Consolidated Statement of Income

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Revenue	127,536	116,160
Cost of sales	(37,013)	(28,678)
Gross profit	90,523	87,482
Selling, general, and administrative expenses	(31,086)	(23,898)
Research and development costs	(36,252)	(32,404)
Other income	113	85
Other expenses	(1,303)	(611)
Operating profit	21,995	30,653
Finance income	1,428	1,381
Finance costs	(773)	(783)
Profit before tax	22,650	31,250
Income tax expense	(5,019)	(7,087)
Profit for the period	17,631	24,163
Profit for the period attributable to:		
Owners of the Company	17,673	24,151
Non-controlling interests	(42)	12
Profit for the period	17,631	24,163
Earnings per share		
Basic earnings per share (Yen)	37.62	51.40
Diluted earnings per share (Yen)	37.58	51.38

Condensed Interim Consolidated Statement of Comprehensive Income

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit for the period	17,631	24,163
Other comprehensive income:		
Items that will not be reclassified to profit or loss:		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	1,648	5,786
Remeasurements of defined benefit plans	11	(33)
Total of items that will not be reclassified to profit or loss	1,660	5,752
Items that may be reclassified subsequently to profit or loss:		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(2)	—
Exchange differences on translation of foreign operations	(10,510)	4,965
Net fair value gain (loss) on cash flow hedge	(1,981)	7
Total of items that may be reclassified subsequently to profit or loss	(12,493)	4,972
Total other comprehensive income	(10,834)	10,724
Total comprehensive income for the period	6,797	34,888
Comprehensive income for the period attributable to:		
Owners of the Company	6,839	34,889
Non-controlling interests	(41)	(1)
Total comprehensive income for the period	6,797	34,888

(3) Condensed Interim Consolidated Statement of Changes in Equity

Three months ended June 30, 2025

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2025	17,358	17,458	(63,063)	19,789	790,908	782,451	5,751	788,203
Profit for the period					17,673	17,673	(42)	17,631
Other comprehensive income				(10,834)		(10,834)	1	(10,834)
Total comprehensive income for the period	–	–	–	(10,834)	17,673	6,839	(41)	6,797
Cash dividends					(18,791)	(18,791)	(6)	(18,797)
Share-based payments		12				12		12
Transfer from other components of equity to retained earnings				(189)	189	—		—
Transfer to non-financial assets				2,127		2,127		2,127
Total transactions with the owners	—	12	—	1,937	(18,602)	(16,652)	(6)	(16,658)
Balance as of June 30, 2025	17,358	17,470	(63,063)	10,892	789,980	772,638	5,704	778,342

Three months ended June 30, 2026

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2026	17,358	17,378	(62,770)	48,674	830,086	850,727	5,917	856,643
Profit for the period					24,151	24,151	12	24,163
Other comprehensive income				10,738		10,738	(14)	10,724
Total comprehensive income for the period	—	—	—	10,738	24,151	34,889	(1)	34,888
Purchase of treasury shares			(0)			(0)		(0)
Cash dividends					(18,796)	(18,796)	(6)	(18,803)
Share-based payments		12				12		12
Transfer from other components of equity to retained earnings				85	(85)	—		—
Total transactions with the owners	—	12	(0)	85	(18,881)	(18,785)	(6)	(18,792)
Balance as of June 30, 2026	17,358	17,389	(62,770)	59,497	835,356	866,831	5,909	872,740

(4) Condensed Interim Consolidated Statement of Cash Flows

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	22,650	31,250
Depreciation and amortization	9,238	8,980
Interest and dividend income	(1,427)	(1,303)
Interest expense	571	584
(Increase) decrease in inventories	3,592	1,994
(Increase) decrease in trade and other receivables	(8,061)	5,379
Increase (decrease) in trade and other payables	(25,079)	(13,035)
Increase (decrease) in retirement benefit liabilities	90	222
Increase (decrease) in accrued consumption tax	5	(2,584)
Other	5,173	(783)
Subtotal	6,752	30,705
Interest received	291	159
Dividends received	949	1,010
Interest paid	(571)	(584)
Income taxes paid	(4,048)	(30,236)
Net cash provided by (used in) operating activities	3,373	1,053
Cash flows from investing activities		
Purchases of property, plant, and equipment	(2,250)	(1,989)
Proceeds from sales of property, plant, and equipment	0	8
Purchases of intangible assets	(45,792)	(3,640)
Proceeds from sales of intangible assets	0	8,401
Purchases of investments	(170)	(834)
Proceeds from sales and redemption of investments	5,383	1,736
Proceeds from withdrawal of time deposits	386	—
Other	(600)	(259)
Net cash provided by (used in) investing activities	(43,043)	3,423
Cash flows from financing activities		
Dividends paid	(17,396)	(17,466)
Dividends paid to non-controlling interests	(6)	(6)
Net increase/decrease in short-term loans	—	3,947
Repayment of long-term loans	(7,500)	(7,500)
Repayments of lease liabilities	(854)	(824)
Purchases of treasury shares	—	(0)
Net cash provided by (used in) financing activities	(25,757)	(21,850)
Net increase (decrease) in cash and cash equivalents	(65,426)	(17,374)
Cash and cash equivalents at the beginning of the period	204,567	237,046
Effects of exchange rate changes on cash and cash equivalents	(150)	(130)
Cash and cash equivalents at the end of the period	138,991	219,542

(5) Notes to Condensed Interim Consolidated Financial Statements

(Note Regarding Assumption of Going Concern)

Not Applicable

(Segment Information)

Segment information is omitted herein because our group’s business is a single segment of the pharmaceutical business.

(Significant Subsequent Event)

Not Applicable

4. Supplementary Information

(1) Sales Revenue and Forecast of Major Products

(Billions of yen)

Product name	Three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)			FY 2026 Forecast (April 1, 2026 to March 31, 2027)		
	Result	YoY		Forecast	YoY	
		Change	Change (%)		Change	Change (%)
<Domestic>						
Opdivo Intravenous Infusion	**28.2**	(1.2)	(4.1%)	**120.0**	5.7	5.0%
Orencia for Subcutaneous Injection	**4.8**	(2.2)	(31.6%)	**19.0**	(7.6)	(28.6%)
Velexbru Tablets	**3.2**	0.1	4.6%	**12.0**	0.1	0.9%
Parsabiv Intravenous Injection	**2.4**	0.2	10.0%	**10.0**	1.0	11.2%
Ongentys Tablets	**2.6**	0.4	16.9%	**10.0**	1.0	11.5%
Glactiv Tablets	**3.1**	(0.4)	(11.8%)	**9.5**	(3.7)	(28.1%)
Braftovi Capsules	**2.0**	0.7	51.1%	**8.5**	2.9	51.5%
Kyprolis for Intravenous Infusion	**1.8**	(0.2)	(12.0%)	**7.0**	(0.5)	(6.6%)
<Overseas>						
Opdivo	**3.5**	0.2	7.3%	**13.0**	(1.2)	(8.2%)
QINLOCK	**11.7**	2.8	31.5%	**43.0**	4.6	12.1%
ROMVIMZA	**4.1**	3.1	289.3%	**19.0**	10.7	129.4%

Notes: 1. Sales revenue of domestic products is shown in a gross sales basis (shipment price).
2. Sales revenue of overseas products is shown in a net sales basis.

(2) Details of Sales Revenue

(Billions of yen)

	Three months ended June 30, 2025	**Three months ended June 30, 2026**
Revenue of goods and products	87.8	**67.9**
Royalty and others	39.8	**48.2**
Total	127.5	**116.2**

Note: In "Royalty and others", royalty revenue of Opdivo from Bristol-Myers Squibb Company is included, which is ¥29.2 billion for the First quarter (three months) ended June 30, 2025, and ¥34.7 billion for the First quarter (three months) ended June 30, 2026. Royalty revenue of Keytruda® from Merck & Co., Inc. is included, which is ¥6.5 billion for the First quarter (three months) ended June 30, 2025, and ¥7.9 billion for the First quarter (three months) ended June 30, 2026.

(3) Revenue by Geographic Area

(Billions of yen)

	Three months ended June 30, 2025	**Three months ended June 30, 2026**
Japan	75.3	**49.1**
USA	45.0	**58.1**
Asia	4.5	**4.4**
Europe	2.4	**4.1**
Others	0.4	**0.4**
Total	127.5	**116.2**

Notes: Revenue by geographic area is presented on the basis of the place of customers.

Main Status of Development Pipelines

As of July 31, 2026, we have listed our pipeline, which includes projects that we are developing clinically either independently (including through our wholly-owned subsidiaries) or in collaboration with partners, as well as those for which we hold contractual rights for potential future clinical development or commercialization. Please note that this does not encompass all development activities.

- For regions where we have obtained marketing approval for any indication, the product name is also listed.
- The development stage is indicated for the main countries/regions where we hold rights.
- The start date for clinical trials is based on the date of acceptance of the clinical trial notification, unless otherwise specified.
- Regarding in-house/in-license products, those in which the Ono Group was involved in the drug discovery process during joint research are considered in-house, while those for which we hold commercialization rights are considered in-license. For limited rights, the specific countries/regions are listed separately.

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Unresectable anaplastic thyroid cancer (Combination with lenbatinib)	Filed (Japan) 26/06	In-house (Co-development with Bristol-Myers Squibb)
		Hepatocellular carcinoma, Adjuvant therapy	P3	In-house (Co-development with Bristol-Myers Squibb)
		Non-small cell lung cancer, Neoadjuvant and adjuvant therapy (Combination with chemotherapy)	P3	In-house (Co-development with Bristol-Myers Squibb)
		Rhabdoid tumor, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
		Richter transformation, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Primary central nervous system lymphoma, Second-line treatment and beyond	Filed (USA) 25/12	In-house
		Relapsed or refractory secondary central nervous system lymphoma (SCNSL)	Filed (Japan) 26/6	In-house
		Primary central nervous system lymphoma, Second-line treatment and beyond	P3	In-house
		Primary central nervous system lymphoma, First-line treatment	P2	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
DCC-2618 Ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor, Second-line treatment for patients with KIT exon 11+17/18 mutation	P3	In-house
		Gastrointestinal stromal tumor, Fourth-line treatment	Filed (Japan) 26/03, P1	In-house
ONO-0530 sapablursen (Subcutaneous injection)	TMPRSS6 gene expression inhibitor (Oligonucleotide)	Polycythemia vera	P3	In-license (Ionis Pharmaceuticals, Inc)
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Gastric cancer, First-line treatment (Standard treatment (combination with Opdivo and chemotherapy))	P2	In-house
		Colorectal cancer, First-line treatment (combination with Opdivo and standard treatment)	P2	In-house
		Non-small cell lung cancer, Second-line treatment (combination with Opdivo and standard treatment)	P1	In-house
ONO-4482 relatlimab (Intravenous injection)	Anti-LAG-3 antibody	Melanoma, Second-line treatment and beyond (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-7427 (Intravenous injection)	Anti-CCR8 antibody	Solid tumor (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-3116 inlexisertib (Oral medication)	ULK inhibitor	Advanced malignancies (Combination with ripretinib)	P1/2	In-house
DCC-3009 (Oral medication)	Pan-KIT inhibitor	Gastrointestinal stromal tumor	P1/2	In-house

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4538HSC (Subcutaneous injection)	A human anti-human PD-1monoclonal antibody	Pediatric malignant solid tumors, epithelioid sarcoma	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
		Solid tumor	P1	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-2812 (Oral medication)	GCN2 activator	Renal cell carcinoma, urothelial carcinoma, castration-resistant prostate cancer	P1	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1 x CD3 bispecific antibody	T-cell lymphoma, Second-line treatment	P1	In-house
ONO-8250 (Intravenous injection)	iPS cell-derived HER2-targeted CAR-T cell therapeutics	HER2-expressing solid tumors	P1	In-house (Co-development with Fate Therapeutics, Inc.)
ONO-7428 (Intravenous injection)	Anti-ONCOKINE-1 antibody	Solid tumor	P1	In-license (NEX-I, Inc.)
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	P1	In-license (LigaChem Biosciences, Inc.)

(Areas Other than Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-2017 Cenobamate (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures	Filed (Japan) 25/09	In-license (Japan) (SK Biopharmaceuticals)
		Partial-onset seizures (Pediatric)	P3	In-license (Japan) (SK Biopharmaceuticals)
		Primary generalized tonic-clonic seizures	P3	In-license (Japan) (SK Biopharmaceuticals)
ONO-4059 Tirabrutinib hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Steroid-resistant pemphigus	P3	In-house
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Immunoglobulin A nephropathy (IgAN)	P3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
		Membranous nephropathy	P2b/3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
ONO-5532 Gel-One (Intra-articular injection)	Cross-linked hyaluronate	Knee osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
		Hip osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
DCC-3014 vimseltinib ROMVIMZA (Oral medication)	CSF-1R inhibitor	Tenosynovial giant cell tumor	P2 (Japan)	In-house
		cGvHD	P2	In-house
ONO-2808 (Oral medication)	S1P5 receptor agonist	Multiple system atrophy	P2	In-house
ONO-2020 (Oral medication)	Epigenetic regulation	Alzheimer's disease	P2	In-house
		Agitation associated with dementia due to Alzheimer's disease	P2	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-1110 (Oral medication)	Endocannabinoid regulation	Postherpetic neuralgia	P2	In-house
		Major depressive disorder	P2	In-house
		Fibromyalgia	P2	In-house
		Social anxiety disorder	P2	In-house
		Hunner type interstitial cystitis	P2	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1×CD3 bispecific antibody	Autoimmune disease	P1	In-house
ONO-4915 (Intravenous injection /Subcutaneous injection)	PD-1×CD19 bispecific antibody	Autoimmune disease	P1	In-house
ONO-2416 (Oral medication)		Psychiatric disease	P1	In-house
ONO-3310 (Oral medication)		Kidney disease	P1	In-house
ONO-6414 (Oral medication)		Autoimmune disease	P1	In-house
ONO-3401 (Oral medication)		Neurological disease	P1	In-house

The change from the announcement of financial results for the fiscal year ended March 31, 2026, is as follows:
(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-4538HSC (Subcutaneous injection)	A human anti-human PD-1 monoclonal antibody	Pediatric malignant solid tumors, epithelioid sarcoma	In May 2026, phase I/II of ONO-4538HSC was initiated in Japan for the treatment of pediatric malignant solid tumors and epithelioid sarcoma.
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Unresectable anaplastic thyroid cancer, (Combination with lenvatinib)	In June 2026, an application of ONO-4538 was filed in Japan for the treatment of unresectable anaplastic thyroid.
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Central nervous system involvement of malignant lymphoma (for patients refractory to or ineligible for existing therapies)	In June 2026, an application of Velexbru (BTK inhibitor) was filed in Japan for Central nervous system involvement of malignant lymphoma (for patients refractory to or ineligible for existing therapies).

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
DCC-3014 vimseltinib ROMVIMZA (Oral medication)	CSF-1R inhibitor	Tenosynovial giant cell tumor	In July 2026, phase II of DCC-3014 was initiated in Japan for the treatment of tenosynovial giant cell tumor.
ONO-3401 (Oral medication)		Neurological disease	In July 2026, phase I of ONO-3401 was initiated in Japan for the treatment of neurological disorder.